



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of

: **Confirmation No. 6705**

Kunihiko IIZUKA et al.

: Docket No. 2001-1460A

Serial No. 09/937,221

: Group Art Unit 1625

Filed July 18, 2002

: Examiner Bernard I. Dentz

AGENT FOR PROPHYLAXIS AND  
TREATMENT OF INTERSTITIAL  
PNEUMONIA AND PULMONARY  
FIBROSIS

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

**RECEIVED**  
NOV 14 2003  
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. .

1a. [] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☒ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☒ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a. ☒ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:

- a. ☐ a full or partial English language translation submitted herewith,
- b. ☐ a foreign patent office search report (in the English language) submitted herewith,
- c. ☐ the concise explanation contained in the specification of the present application at page,
- d. ☐ the concise explanation set forth in the attached English language abstract,
- e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A Supplementary Partial European Search Report citing one or more of the references is enclosed.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 7, 2003

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: November 7, 2003

ATTY DOCKET NO.  
2001-1460ASERIAL NO.  
09/937,221APPLICANT  
Kunihiko IIZUKA et al.FILING DATE  
July 18, 2002GROUP  
1624

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

RECEIVED  
NOV 14 2003  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AH	98-47892	10/1998	WO			
	AI						
	AJ						
	AK						
	AL						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Database BIOSIS Online abstract of Kunitake et al., "Expression of p53, p21 (Waf1/Cip1/Sdi1) and Fas antigen in collagen vascular and granulomatous lung diseases", European Respiratory Journal, Vol. 12, No. 4, October, 1998.
	AN	Database BIOSIS Online abstract of Kuwano Kazuyoshi et al., "P21-Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis", American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 2, part 1, 1996, pp. 477-483.
	AO	Database BIOSIS Online abstract of Rauf Brandt et al., "Serum Oncoproteins and Growth Factors in Asbestosis and Silicosis Patients", International Journal of Cancer, Vol. 50, No. 6, 1992, pp. 881-885.
	AP	Database BIOSIS Online abstract of K. Kawano et al., "The roles of apoptosis in lung injury and fibrosis", Journal of the Japanese Respiratory Society, Vol. 36, No. 9., September 1998, pp. 739-744.

EXAMINER

DATE CONSIDERED